MONEY

Fresenius Kabi and Formycon Receive U.S. FDA Approval for Biosimilar Otulfi™* (ustekinumab-aauz)

Tomas Kauer - ModeratorTomas Kauer - Moderator
Oct 1, 2024 - 04:00
Fresenius Kabi and Formycon Receive U.S. FDA Approval for Biosimilar Otulfi™* (ustekinumab-aauz)
Read More

Tags:

Previous Article

Retractable Technologies, Inc. Declares Dividends to Series II and III Class B P...

Next Article

The PG&E Corporation Foundation and California Fire Foundation Announce Wildfire...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Tomas Kauer - Moderator
Tomas Kauer - Moderator

Related Posts

Russian bomb strikes Kharkiv apartment building, one dead, 42 injured, officials say

Russian bomb strikes Kharkiv apartment building, one de...

Tomas Kauer - Mode... Sep 16, 2024

23andMe Therapeutics Announces Phase 2 Results for Two Additional Cancer Cohorts and Correlative Biomarker Data from 23ME-00610 Study

23andMe Therapeutics Announces Phase 2 Results for Two ...

Tomas Kauer - Mode... Sep 15, 2024

US officials question if easing Ukraine weapons restrictions would pay off

US officials question if easing Ukraine weapons restric...

Tomas Kauer - Mode... Sep 14, 2024